Toggle light / dark theme

While satellite imaging lets researchers observe the outer life of plankton populations, the complex genetics in microscopic marine life have made looking inward more challenging. According to a new study published in Nature Methods, researchers from the University of East Anglia were able to deliver and express foreign DNA in 13 species that have never before transformed. They were also able to evaluate the potential cause of non-transformation in 17 other species; in turn, laying the foundation for an expanded understanding of genomes discovered in plankton.

The sheer variety of plankton potential — from antibacterial compounds to antiviral and antifungal solutions — makes this a worthwhile endeavor. If scientists can create reliable methods to modify phytoplankton, it should be possible to reduce their toxic impact, better control their bloom cycle and even increase the photosynthetic output — all critical in the fight to keep our oceans blue and our terra firma green.

As noted by Science Magainze, the international research team used a variety of methods to modify plankton DNA. For some species, shooting tiny gold or tungsten particles covered with DNA through cell walls produced the best result. For others, jolts of electricity made cell walls “leaky” and allowed new DNA to seep through. Specific protist successes included modification of a fish-killing toxic plankton species, and one that infects both mollusks and amphibians. While these discoveries don’t present a complete understanding of the genetics in microscopic marine life, they provide a key testing protocol: By modifying genetic structure and then observing how plankton react, teams could uncover ways to boost antibiotic resistance or lower infectious impact. According to lead UK study author Thomas Mock, “These insights will improve our understanding about their role in the oceans, and they are invaluable for biotechnological applications such as building factories for biofuel or the production of bioactive compounds.”

In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19.

One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans.

The FDA issued an E… See More

The nitazoxanide plus atazanavir for COVID-19 study — full text view.


Since the outbreak of the novel coronavirus disease in 2019 (COVID-19), an unprecedented global search for potential therapeutics and vaccines is ongoing. In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19. One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans.

In this pilot study, 98 COVID-19 patients will be recruited into two group. The 49 patients in group 1 will receive the standard of care determined by their primary care providers while the 49 patients will receive both the standard of care combined with the two study drugs. Patients in group 2 will receive the study drugs for 14 days and all patients will be monitored for a total of 28 days.

Keith Comito, president of Life Extension Advocacy Foundation, joins me for a discussion to preview the 2020 Eding Age Related Diseases conference, to be held online, August 20–21, 2020. Go HERE to register for the conference, and use discount code SeekingDelphiEARD

You can subscribe to Seeking Delphi™ on Apple podcasts, PlayerFM, MyTuner, Listen Notes, and YouTube. You can also follow us on twitter @Seeking_Delphi and Facebook.

EPFL spin-off SEED Biosciences has developed a pipetting robot that can dispense individual cells one by one. Their innovation allows for enhanced reliability and traceability, and can save life-science researchers time and money.

The engineers at SEED Biosciences, an EPFL spin-off, have come up with a unique pipetting robot that can isolate single with the push of a button—without damaging the cells. Their device also records the cells’ electrical signature so that they can be traced. While this innovation may seem trivial, it can save researchers several weeks of precious time and speed up development work in pharmaceuticals, cancer treatments and personalized medicine. The company began marketing its device this year.

Vietnam has been one of the countries that have well managed COVID-19 pandemic with only 383 cases, and no deaths have been reported (updated on 20th July). Immune Nutrition from ColosIgG 24h colostrum is one of the factors contribute fighting off COVID-19 in VietnamnnPrior to this pandemic, being aware that strengthening the immune system is very important for health, especially for children, the Vietnamese Ministry of Health cooperated with VitaDairy Company to organise a series of seminars on Immune Nutrition in big cities. As a result, at the end of 2019 when the COVID-19 outbreak started, people understood the importance of the immune system and the value of immune nutrition from ColosIgG 24h colostrum.nn


P rior to this pandemic, being aware that strengthening the immune system is very important for health, especially for children, the Vietnamese Ministry of Health cooperated with VitaDairy Company to organise a series of seminars on Immune Nutrition in big cities. As a result, at the end of 2019 when the COVID-19 outbreak started, people understood the importance of the immune system and the value of immune nutrition from ColosIgG 24h colostrum. In addition to the seminars, Vietnamese Ministry of Health has taken many quick and appropriate actions to deal with the pandemic. Thanks to these actions, up to now, Vietnam is one of the countries that have very well managed the COVID-19 pandemic.

VitaDairy As The Ministry of Health’s Partner — “With Competence And A Strong Will”

In parallel with the seminar series, VitaDairy became the No. 1 colostrum company in Vietnam while making a hundred million dollar deal with the leading colostrum group in the US — PanTheryx — to exclusively import ColosIgG 24h colostrum to Vietnam. Joining hands to combat the pandemic, VitaDairy donated 1 million ColosIgG 24h colostrum products to the Vietnamese people and donated protective equipment to health workers with a total sponsorship of nearly 500,000 USD.

Researchers at the University of Alabama at Birmingham, and Southern Research, have identified a new drug candidate that they claim could represent a “distinct and innovative” approach to treating type 1 and type 2 diabetes. The small molecule drug, designated SRI-37330, inhibits the expression of a protein known as TXNIP—which the team had previously identified as a top glucose-induced gene—in both mouse and human islets.nnResults from the researchers’ preclinical studies suggested that SRI-37330 acts on pancreatic islet cells that produce glucagon and insulin, and also acts on the liver. The findings showed that the drug could have therapeutic effects against diabetes, in both lean and obese individuals. Tests on isolated human and mouse pancreatic islets, on mouse and rat cell cultures, and in animal models of both type 1 and type 2 diabetes, demonstrated that SRI-37330 improved diabetes-related hyperglycemia, and hyperglucagonemia; reduced the excessive production of glucose by the liver; and reduced fatty liver, or hepatic steatosis.nn


Studies showed non-toxic, orally bioavailable small molecule effectively rescued mice from models of type 1 and type 2 diabetes, and reduced fatty liver.

Tesla and CureVac have collaborated on a patent for an RNA bioreactor.

Although there are no human vaccines made with RNA, the technology could break through on COVID-19 (coronavirus).

The bioreactor works by combining chemical agents in an egg-shaped magnetic mixer.


Tesla has taken on the manufacturing role for a biotech startup with a revolutionary new RNA reactor concept. A tipster recently alerted Electrek to this year-old patent application, which lists both Tesla and German startup CureVac.

CureVac has made the news recently because of a misinformed factoid that it was being purchased by President Donald Trump. That’s partly because CureVac is working on the groundwork for a COVID-19 (coronavirus) vaccine. Today, the European Investment Bank (EIB) reported that it’s awarded an $84 million loan to CureVac to accelerate that vaccine development process.